安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMGN 安进

盘前交易 07-07 05:34:29 EDT

298.24

+1.39

+0.47%

盘前297.36

-0.88-0.30%

05:30 EDT

最高298.99	最低295.51	成交量151.85万
今开297.00	昨收296.85	日振幅1.17%
总市值1,604亿	流通市值1,600亿	总股本5.38亿
成交额4.52亿	换手率0.28%	流通股本5.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"安进","latestPrice":298.24,"timestamp":1751562000000,"preClose":296.85,"halted":0,"volume":1518516,"hourTrading":{"tag":"盘前","latestPrice":297.36,"preClose":298.24,"latestTime":"05:30 EDT","volume":221,"amount":65805.26497999999,"timestamp":1751880602863},"delay":0,"floatShares":536332816,"shares":537706118,"eps":10.942775,"marketStatus":"盘前交易","change":1.39,"latestTime":"07-07 05:34:29 EDT","open":297,"high":298.99,"low":295.51,"amount":452475401.4036,"amplitude":0.011723,"askPrice":298.67,"askSize":5,"bidPrice":295.12,"bidSize":28,"shortable":3,"etf":0,"ttmEps":10.942775,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1751895000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":298.24,"dividendRate":0.030613,"preHourTrading":{"tag":"盘前","latestPrice":297.36,"preClose":298.24,"latestTime":"05:30 EDT","volume":221,"amount":65805.26497999999,"timestamp":1751880602863},"postHourTrading":{"tag":"盘后","latestPrice":298.52,"preClose":298.24,"latestTime":"16:58 EDT","volume":67238,"amount":20053493.4365,"timestamp":1751576339366},"volumeRatio":0.9627128334927201,"impliedVol":0.2721,"impliedVolPercentile":0.257},"requestUrl":"/m/hq/s/AMGN/tweets","defaultTab":"tweets","newsList":[{"id":"1173631661","title":"晨星：下半年应该寻觅有反弹机会的美股低价股","url":"https://stock-news.laohu8.com/highlight/detail?id=1173631661","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173631661?lang=zh_cn&edition=full","pubTime":"2025-07-03 14:46","pubTimestamp":1751525199,"startTime":"0","endTime":"0","summary":"对于许多预计今年下半年将动荡不安的投资者而言，医疗保健股可能是一个避风港。相比之下，整个标普500指数的远期市盈率为23倍。礼来目前的远期市盈率为36倍。塞克拉指出，医疗保健股相对较低的估值和高于平均水平的股息收益率，为投资者进入下半年提供了“安全边际”。与此同时，标普500指数估值开始趋于合理，而关税和美国联邦赤字带来的风险仍在持续。","market":"us","thumbnail":"https://community-static.tradeup.com/news/c2f1c792ca2589196df0474972f2a212","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/c2f1c792ca2589196df0474972f2a212"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"晨星：下半年应该寻觅有反弹机会的美股低价股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","JNJ","MRK","UNH"],"gpt_icon":1},{"id":"2548417356","title":"Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2548417356","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548417356?lang=zh_cn&edition=full","pubTime":"2025-07-04 13:01","pubTimestamp":1751605260,"startTime":"0","endTime":"0","summary":"Eli Lilly and Danish pharma giant Novo Nordisk are dominating the market for weight-loss drugs. But a number of competitors are hot on their heels.While Lilly and Novo are still the only two companies with approved weight-loss drugs on sale in the U.S., others are coming for a share of the growing sector.Any way you slice it, the market for weight-loss drugs like the so-called GLP-1 medication made by Lilly and Novo is likely to be huge. Morningstar is one of the most optimistic on this potential, seeing a $200 billion market by 2031.Goldman Sachs cut its estimate in April to $95 billion by 2030, down from $130 billion. That is arguably still a very large number and has attracted more companies to the lucrative industry.Both well-established pharma companies as well as smaller, clinical-stage firms are investing heavily to be able to someday compete with Lilly and Novo.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"礼来和诺和是减肥药之王。为他们的王冠而来的公司。——Barrons.com","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GB00BDT5M118.USD","LU1023059063.AUD","VKTX","LU1868837136.USD","LU2023250504.SGD","NVO","LU0640476718.USD","LU2324357040.USD","IE00BZ1G4Q59.USD","IE0004445239.USD","LU0006306889.USD","LU2237443465.HKD","LU0456855351.SGD","IE00BJT1NW94.SGD","LU0689472784.USD","IE00BFTCPJ56.SGD","LU0323591593.USD","SGXZ81514606.USD","LU0823416689.USD","SGXZ31699556.SGD","LU0097036916.USD","LU1712237335.SGD","IE00BK4W5L77.USD","AMGN","LU0786609619.USD","LU1868836914.USD","LU1974910355.USD","LU0079474960.USD","LU2357305700.SGD","LU2602419157.SGD","IE00BK4W5M84.HKD","LU2750360641.GBP","SG9999001176.SGD","LU1917777945.USD","LU2471134796.USD","LLY","LU2237443895.HKD","LU2361044949.HKD","BK4599","BK4139","LU0266013472.USD","LU0320765059.SGD","LU1057294990.SGD","LU2456880835.USD","LU2461242641.AUD","LU2242646821.SGD","LU2237443978.SGD","LU1571399168.USD","LU1366192091.USD","LU0106261372.USD"],"gpt_icon":1},{"id":"2548331238","title":"安进7月3日成交额为4.53亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548331238","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548331238?lang=zh_cn&edition=full","pubTime":"2025-07-04 09:16","pubTimestamp":1751591785,"startTime":"0","endTime":"0","summary":"美东时间2025年7月3日，安进成交额为4.53亿美元，成交额较昨日减少33.15%，当日成交量为151.85万股。安进于2025年7月3日涨0.47%，报298.24美元，该股过去5个交易日涨6.85%，年初至今涨16.37%，过去60日涨3.87%。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704091651a72da3b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023059063.AUD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU1571399168.USD","IE00B4R5TH58.HKD","LU2089984988.USD","LU0109394709.USD","LU1983299246.USD","LU1057294990.SGD","BK4588","AMGN","IE00BJJMRZ35.SGD","BK4599","IE0002141913.USD","LU0058720904.USD","BK4585","LU2468319806.SGD","LU0289739699.SGD","BK4566","LU2112291526.USD","IE0009355771.USD","LU0868494617.USD","IE00B2B36J28.USD","LU0122379950.USD","SG9999001440.SGD","LU0320765992.SGD","BK4139","BK4533","LU2242652126.USD","BK4581","BK4534","LU1061106388.HKD"],"gpt_icon":0},{"id":"2548733304","title":"从“减重效率”到“减重质量”，GLP-1“战争”下半场逻辑剧变","url":"https://stock-news.laohu8.com/highlight/detail?id=2548733304","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548733304?lang=zh_cn&edition=full","pubTime":"2025-07-04 07:36","pubTimestamp":1751585809,"startTime":"0","endTime":"0","summary":"司美格鲁肽与替尔泊肽均成为“药王级”产品，似乎GLP-1已然兑现了市场对它的期待。两大行业巨头礼来与诺和诺德，看似稳坐云端宝座，实则危机四伏，各路豪强对GLP-1下半场虎视眈眈。GLP-1争夺战并未结束，即将开启的下半场或将出现更大规模的拼杀。根据辉瑞预测，2030年GLP-1市场的规模将达到约900亿美元，口服产品预计到2030年将占据GLP-1市场约30%的份额，主要原因是患者对口服制剂的偏好较高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704074156a72d7aa3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02269","06855","BK1100","BK1585","01877","NVO","02359","02096","BK1589","01952","BK1583","01801","02142","00853","03692","LLY","02696","600276","AMGN","06160","06618"],"gpt_icon":1},{"id":"2548895493","title":"Amgen’s Innovative Approach: Self-Administered Rocatinlimab for Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2548895493","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548895493?lang=zh_cn&edition=full","pubTime":"2025-07-04 00:14","pubTimestamp":1751559251,"startTime":"0","endTime":"0","summary":"Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 study titled ‘A Phase 3, Multicenter, R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-innovative-approach-self-administered-rocatinlimab-for-atopic-dermatitis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"安进创新方法：自我给药Rocatinlimab治疗特应性皮炎","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-innovative-approach-self-administered-rocatinlimab-for-atopic-dermatitis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","LU0889565916.HKD","BK4581","LU0289739699.SGD","BK4534","LU1057294990.SGD","LU0109394709.USD","LU1061106388.HKD","LU0122379950.USD","BK4566","LU2089984988.USD","SG9999001440.SGD","BK4533","IE0002141913.USD","IE0009355771.USD","LU1023059063.AUD","BK4139","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2242652126.USD","LU1571399168.USD","IE00BJJMRZ35.SGD","AMGN","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4588","BK4585","LU0868494617.USD","LU0320765992.SGD","LU2112291526.USD","LU2468319806.SGD","LU2242646821.SGD","LU1983299246.USD","BK4599"],"gpt_icon":0},{"id":"2548389514","title":"Amgen’s Tarlatamab Study: A Potential Game-Changer in Small Cell Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2548389514","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548389514?lang=zh_cn&edition=full","pubTime":"2025-07-04 00:12","pubTimestamp":1751559163,"startTime":"0","endTime":"0","summary":"Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 1 study titled ‘A Phase 1 Study Evaluatin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-tarlatamab-study-a-potential-game-changer-in-small-cell-lung-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"安进的Tarlatamab研究：小细胞肺癌治疗的潜在游戏规则改变者","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-tarlatamab-study-a-potential-game-changer-in-small-cell-lung-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","LU2468319806.SGD","LU2112291526.USD","IE00BJT1NW94.SGD","LU1983299246.USD","IE0002141913.USD","AMGN","LU0109394709.USD","IE00B2B36J28.USD","BK4599","LU2242652126.USD","LU0868494617.USD","LU1061106388.HKD","BK4585","LU1571399168.USD","LU2242646821.SGD","IE00B4R5TH58.HKD","BK4581","BK4588","IE00BJJMRZ35.SGD","BK4139","LU0320765992.SGD","LU0889565916.HKD","LU1023059063.AUD","BK4533","BK4534","IE00BFTCPJ56.SGD","IE0009355771.USD","LU2089984988.USD","BK4566","LU0122379950.USD","LU0289739699.SGD","SG9999001440.SGD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2548434498","title":"安进抗FGFR2b单抗在一线胃癌治疗后期试验中取得积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2548434498","media":"药事纵横","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548434498?lang=zh_cn&edition=full","pubTime":"2025-07-03 06:03","pubTimestamp":1751493795,"startTime":"0","endTime":"0","summary":"自安进公司斥资近20亿美元收购Five Prime公司及其针对FGFR2b的单克隆抗体以来，已过去四年多。6月30日，安进公司公布了一项胃癌III期临床试验的主要结果，显示该单克隆抗体达到了主要生存终点。此外，34.2%接受贝马妥珠单抗治疗的患者因不良事件而中断治疗，而安慰剂组仅为5.2%。此外，双方合作伙伴还在开展一项贝马妥珠单抗联合化疗及百时美施贵宝公司的纳武利尤单抗作为胃癌一线治疗的III期试验，预计今年下半年公布数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703060541a72b3f1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LU1571399168.USD","LU1057294990.SGD","LU2468319806.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4533","LU1983299246.USD","LU0320765992.SGD","LU0289739699.SGD","AMGN","BK4599","LU2089984988.USD","SG9999001440.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","BK4585","LU0868494617.USD","BK4534","LU1061106388.HKD","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU2242652126.USD","IE00BFTCPJ56.SGD","BK4139","LU0122379950.USD","LU0109394709.USD","BK4581","LU0058720904.USD","BK4588","BK4566","LU2242646821.SGD","IE0002141913.USD","LU2112291526.USD"],"gpt_icon":0},{"id":"2548179810","title":"Amgen Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2548179810","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548179810?lang=zh_cn&edition=full","pubTime":"2025-07-03 04:35","pubTimestamp":1751488500,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Amgen Inc.  rose 2.18% to $296.85 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  rising 0.47% to 6,227.42 and the Dow Jones Industrial Average  falling 0.02% to 44,484.42.This was the stock's third consecutive day of gains.Amgen Inc. closed 14.42% short of its 52-week high of $346.85, which the company achieved on July 25th.The stock outperformed some of its competitors Wednesday, as Johnson & Johnson  fell 0.23% to $155.56, Pfizer Inc.  rose 1.12% to $25.32, and AbbVie Inc.  rose 0.40% to $190.75.Trading volume  remained 615,660 below its 50-day average volume of 2.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled July 2, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"安进公司股票在强劲交易日表现优于竞争对手","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"gpt_icon":0},{"id":"2548349798","title":"安进7月1日成交额为10.15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548349798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548349798?lang=zh_cn&edition=full","pubTime":"2025-07-02 09:16","pubTimestamp":1751418979,"startTime":"0","endTime":"0","summary":"美东时间2025年7月1日，安进成交额为10.15亿美元，成交额较昨日增加22.79%，当日成交量为350.30万股。安进于2025年7月1日涨4.05%，报290.52美元，该股过去5个交易日涨4.7%，年初至今涨13.36%，过去60日跌5.41%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702091633a4c9ecb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","BK4566","IE00BFTCPJ56.SGD","LU2242652126.USD","LU0122379950.USD","LU0109394709.USD","LU0058720904.USD","BK4581","IE00B4R5TH58.HKD","LU1983299246.USD","LU1023059063.AUD","LU2112291526.USD","BK4139","IE00B2B36J28.USD","AMGN","LU2242646821.SGD","LU0889565916.HKD","BK4533","SG9999001440.SGD","LU1057294990.SGD","LU2089984988.USD","LU2468319806.SGD","BK4588","LU1061106388.HKD","BK4599","IE00BJT1NW94.SGD","LU0868494617.USD","LU0289739699.SGD","BK4534","IE0009355771.USD","IE0002141913.USD","BK4585","LU1571399168.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2548833168","title":"Why Amgen Stock Popped by 4% Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2548833168","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548833168?lang=zh_cn&edition=full","pubTime":"2025-07-02 06:55","pubTimestamp":1751410500,"startTime":"0","endTime":"0","summary":"Investors continued to snap up shares following Monday's good news from the company.Analysts were generally positive about the latest development, too.As cancer is a persistent and tough challenge, any advancement in its treatment is cause for optimism. While Amgen could have provided more details of the study , the rough outlines of bemarituzumab are encouraging. The company might very well be on the cusp of success with the drug.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"为什么安进股价今天上涨4%","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/07/01/why-amgen-stock-popped-by-4-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4533","LU0109394709.USD","LU1571399168.USD","BK4581","LU2089984988.USD","IE0009355771.USD","LU2242652126.USD","LU2468319806.SGD","BK4585","LU0320765992.SGD","LU1061106388.HKD","LU1983299246.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU2242646821.SGD","LU0058720904.USD","SG9999001440.SGD","BK4588","LU0122379950.USD","LU1057294990.SGD","IE0002141913.USD","LU0889565916.HKD","AMGN","BK4139","BK4599","LU0289739699.SGD","LU0868494617.USD","BK4534","LU1023059063.AUD","LU2112291526.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4566"],"gpt_icon":0},{"id":"2548488432","title":"BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2025-07-01","url":"https://stock-news.laohu8.com/highlight/detail?id=2548488432","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548488432?lang=zh_cn&edition=full","pubTime":"2025-07-02 02:45","pubTimestamp":1751395508,"startTime":"0","endTime":"0","summary":"BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2025-07-01Nasdaq 100 .NDXTop PerformersPercent ChangeGlobalFoundries Inc GFS.OQ+4.0%Old Dominion Freight Line Inc ODFL.OQ+4%Am","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"BUZZ-下午02:45左右纳斯达克表现最高和最低的股票美国东部时间2025-07-01","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nL8N3SY1KF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","ODFL","WBD","BIIB","LU1145028129.USD","IE00B19Z9P08.USD","LU2250418816.HKD","TSLA","AXON","LU1066051498.USD","GFS","PLTR","LU1674673428.USD","BK4588","LU1232071149.USD","BK4232","TSYW.SI","IE00B19Z9Z06.USD","IE00BZ9MQY76.HKD","BK4592","LU0122379950.USD","AMGN","IE00B1XK9C88.USD","LU0109391861.USD","LU2242646821.SGD","LU1674673691.USD","LU0708995401.HKD","LULU","LU2756315664.SGD","LU0320765992.SGD","MSTR","LU1267930730.SGD","LU0109394709.USD","BK4516","BK4598","BK4108","BK4202","LU1861215975.USD","LU1066051225.USD","STRK","BK4547","LU0943347566.SGD","LU2108987350.USD","LU2471134796.USD","BK4613","LU0323591593.USD","BK4612","LU1720051017.SGD","LU0345770993.USD"],"gpt_icon":1},{"id":"2548888141","title":"Dow's 400-Point Rally Highlighted By Gains In Amgen, Merck, Sherwin-Williams, UnitedHealth and Nike Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2548888141","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548888141?lang=zh_cn&edition=full","pubTime":"2025-07-02 00:00","pubTimestamp":1751385631,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Buoyed by positive gains for shares of Amgen and Merck, the Dow Jones Industrial Average is climbing Tuesday morning.Shares of Amgen  and Merck  are contributing to the blue-chip gauge's intraday rally, as the Dow  is trading 300 points  higher.Amgen's shares are up $11.70  while those of Merck are up $2.70, or 3.4%, combining for a roughly 89-point boost for the Dow.Also contributing significantly to the gain are Sherwin-Williams Co. , UnitedHealth , and Johnson & Johnson .A $1 move in any of the Dow's 30 components results in a 6.15-point swing.Data source: Dow Jones Market Data, FactSet. Data compiled July 1, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"安进(Amgen)、默克(Merck)、宣伟(Sherwin-Williams)、联合健康(UnitedHealth)和耐克(Nike)股价上涨，凸显道指上涨400点","themeId":"d37a340c53e6112c243f4878dc27bf6f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNH","SG9999015358.SGD","IE00B19Z3B42.SGD","LU0211331839.USD","AMGN","LU1244550577.SGD","LU1548497426.USD","BK4581","SHW","LU0158827781.USD","LU2360032135.SGD","LU1057294990.SGD","LU2087625088.SGD",".DJI","LU2552382132.HKD","LU0128525929.USD","LU2133065610.SGD","MRK","LU1732799900.SGD","LU0661504455.SGD","LU0128525689.USD","LU0211327993.USD","IE00BKVL7J92.USD","LU2279689827.SGD","LU1674673428.USD","IE00B19Z9P08.USD","IE00BFSS7M15.SGD","IE00BFSS8Q28.SGD","HD","IE00BLSP4452.SGD","BK4109","LU2552382058.USD","SG9999014567.USD","LU1116320901.HKD","SG9999001176.SGD","LU1941712264.USD","LU2430703095.HKD","NKE","SG9999017495.SGD","IE00B1XK9C88.USD","LU0048584097.USD","LU1037948897.HKD","LU1261432733.SGD","LU1974910355.USD"],"gpt_icon":0},{"id":"2548831508","title":"道指盘中涨近1%成分股安进、联合健康、默沙东涨超4%耐克、宣伟家得宝涨超3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548831508","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548831508?lang=zh_cn&edition=full","pubTime":"2025-07-01 23:46","pubTimestamp":1751384785,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NKE","UDOW","DDM","LU0795875086.SGD","LU1699723380.USD","LU2756315664.SGD","SG9999015341.SGD","SG9999014559.SGD","LU0029864427.USD","HD","DJX","LU1261432733.SGD","LU0528227936.USD","BK4533","AMGN","LU0912757837.SGD","LU2361045086.USD","LU1291159041.SGD","BK4585","DXD","LU2271345857.HKD","LU0265550946.USD","LU0211326755.USD","LU2324357040.USD","LU0079474960.USD","MRK","IE00B1XK9C88.USD","LU0211328371.USD","DOG","LU0672654240.SGD","LU2491050071.SGD","LU1720051108.HKD","UNH","LU1267930490.SGD","LU2023251221.USD","IE00B19Z9505.USD","BK4558","SDOW","LU1983299246.USD","YMmain","LU0128525689.USD","IE00BBT3K403.USD","LU0320765646.SGD","MYMmain","LU1674673691.USD","LU0354030511.USD",".DJI","LU1064131342.USD","LU1057294990.SGD","SG9999017495.SGD"],"gpt_icon":0},{"id":"2548000431","title":"安进盘中异动 早盘股价大涨3.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548000431","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548000431?lang=zh_cn&edition=full","pubTime":"2025-07-01 22:39","pubTimestamp":1751380749,"startTime":"0","endTime":"0","summary":"北京时间2025年07月01日22时39分，安进股票出现波动，股价急速上涨3.00%。截至发稿，该股报287.58美元/股，成交量41.1249万股，换手率0.08%，振幅3.05%。安进股票所在的制药行业中，整体涨幅为0.91%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。消息层面，截至22时39分，《TD Cowen维持安进买入评级，维持目标价389美元》资讯为影响安进的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701223909a728abc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4581","BK4533","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4599","LU0109394709.USD","IE00BJT1NW94.SGD","LU0122379950.USD","AMGN","BK4534","LU1023059063.AUD","IE0009355771.USD","BK4588","LU0868494617.USD","BK4585","IE0002141913.USD","LU0889565916.HKD","LU1057294990.SGD","LU1061106388.HKD","LU2089984988.USD","LU0289739699.SGD","LU1571399168.USD","LU0320765992.SGD","LU2112291526.USD","LU1983299246.USD","SG9999001440.SGD","LU2242652126.USD","BK4566","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU2242646821.SGD","LU0058720904.USD","BK4139","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2548200312","title":"Piper Sandler Sticks to Their Buy Rating for Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2548200312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548200312?lang=zh_cn&edition=full","pubTime":"2025-07-01 18:57","pubTimestamp":1751367460,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $328.00. The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-amgen-amgn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"Piper Sandler维持安进(AMGN)的买入评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-amgen-amgn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMGN"],"gpt_icon":0},{"id":"2548725070","title":"Zura Bio Ltd. Announces Eric Hyllengren as New CFO, Succeeding Verender Badial in July 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2548725070","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548725070?lang=zh_cn&edition=full","pubTime":"2025-07-01 18:30","pubTimestamp":1751365834,"startTime":"0","endTime":"0","summary":"Zura Bio Ltd. has announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will replace Verender Badial, who will remain with the company as a non-executive employee through July 31, 2025, to ensure a smooth transition. Hyllengren brings over 20 years of financial leadership experience in the life sciences and biotechnology sectors, previously serving in roles at Atara Biotherapeutics and Amgen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire  on July 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Zura Bio Ltd.宣布Eric Hyllengren担任新任首席财务官，于2025年7月接替Verender Badial","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL91c7hc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","BK4581","LU2089984988.USD","ATRA","LU0868494617.USD","LU2468319806.SGD","BK4588","IE00BJT1NW94.SGD","BK4585","BK4599","IE0002141913.USD","LU2242646821.SGD","LU1571399168.USD","IE00B2B36J28.USD","LU0889565916.HKD","LU1023059063.AUD","SG9999001440.SGD","BK4139","BK4534","IE00B4R5TH58.HKD","LU0320765992.SGD","LU2112291526.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","AMGN","LU0122379950.USD","BK4566","LU2242652126.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4533","LU0058720904.USD","ZURA","LU1061106388.HKD","LU1983299246.USD"],"gpt_icon":0},{"id":"2548073680","title":"Richter Gedeon Secures European Commission Approval for Biosimilar Denosumab Products Junod® and Yaxwer® for Bone Disease and Osteoporosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2548073680","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548073680?lang=zh_cn&edition=full","pubTime":"2025-07-01 15:45","pubTimestamp":1751355943,"startTime":"0","endTime":"0","summary":"Richter Gedeon Secures European Commission Approval for Biosimilar Denosumab Products Junod and Yaxwer for Bone Disease and Osteoporosis. Richter Gedeon Vegyészeti Gyár Nyrt. has received approval from the European Commission for its biosimilar denosumab products, Junod and Yaxwer. These products have been approved for all the same indications as the reference medicines Prolia and Xgeva by Amgen. The indications include the treatment of osteoporosis in postmenopausal women, the prevention of skeletal-related events in patients with bone metastases from solid tumors, and the treatment of unresectable giant cell tumor of bone. The approval follows a comprehensive development program that demonstrated the biosimilarity of Junod and Yaxwer to the reference products regarding quality, safety, and efficacy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Richter Gedeon生物仿制药Denosumab产品Junod获得欧盟委员会批准®和亚克斯韦尔®用于骨病和骨质疏松症","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL1kPhq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU1571399168.USD","LU1057294990.SGD","LU2468319806.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4533","LU1983299246.USD","LU0320765992.SGD","LU0289739699.SGD","AMGN","BK4599","LU2089984988.USD","SG9999001440.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","BK4585","LU0868494617.USD","BK4534","LU1061106388.HKD","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU2242652126.USD","IE00BFTCPJ56.SGD","BK4139","LU0122379950.USD","LU0109394709.USD","BK4581","LU0058720904.USD","BK4588","BK4566","LU2242646821.SGD","IE0002141913.USD","LU2112291526.USD"],"gpt_icon":0},{"id":"2548204225","title":"安进6月30日成交额为8.26亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548204225","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548204225?lang=zh_cn&edition=full","pubTime":"2025-07-01 09:16","pubTimestamp":1751332574,"startTime":"0","endTime":"0","summary":"美东时间2025年6月30日，安进成交额为8.26亿美元，成交额较昨日增加2.71%，当日成交量为296.39万股。安进于2025年6月30日涨0.75%，报279.21美元，该股过去5个交易日涨2.48%，年初至今涨8.95%，过去60日跌7.85%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701091621a727295b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJT1NW94.SGD","LU0889565916.HKD","BK4581","LU0289739699.SGD","BK4534","LU1057294990.SGD","LU0109394709.USD","LU1061106388.HKD","LU0122379950.USD","BK4566","LU2089984988.USD","SG9999001440.SGD","BK4533","IE0002141913.USD","IE0009355771.USD","LU1023059063.AUD","BK4139","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2242652126.USD","LU1571399168.USD","IE00BJJMRZ35.SGD","AMGN","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4588","BK4585","LU0868494617.USD","LU0320765992.SGD","LU2112291526.USD","LU2468319806.SGD","LU2242646821.SGD","LU1983299246.USD","BK4599"],"gpt_icon":0},{"id":"2547409077","title":"Amgen says Phase 3 FORTITUDE-101 clinical trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2547409077","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547409077?lang=zh_cn&edition=full","pubTime":"2025-06-30 22:18","pubTimestamp":1751293129,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy met its primary endpoint of o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-says-phase-3-fortitude-101-clinical-trial-met-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"安进称3期FORTITUDE-101临床试验达到主要终点","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-says-phase-3-fortitude-101-clinical-trial-met-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","AMGN","LU0289739699.SGD","LU0868494617.USD","LU1057294990.SGD","LU0109394709.USD","LU1023059063.AUD","LU0122379950.USD","LU2112291526.USD","BK4139","IE00BJJMRZ35.SGD","LU1983299246.USD","LU2089984988.USD","LU0320765992.SGD","BK4534","LU0058720904.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU2468319806.SGD","IE00B4R5TH58.HKD","BK4599","LU1571399168.USD","LU2242652126.USD","IE0009355771.USD","LU0889565916.HKD","LU2242646821.SGD","BK4585","IE00BJT1NW94.SGD","BK4566","IE00B2B36J28.USD","BK4588","LU1061106388.HKD","BK4581","SG9999001440.SGD"],"gpt_icon":0},{"id":"2547094085","title":"安进公司的胃癌药物达到后期试验目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2547094085","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547094085?lang=zh_cn&edition=full","pubTime":"2025-06-30 21:06","pubTimestamp":1751288762,"startTime":"0","endTime":"0","summary":"安进公司的胃癌药物达到后期试验目标路透6月30日 - 安进公司（Amgen AMGN.O）周一表示，其实验性癌症疗法与化疗相结合，在一项晚期试验中达到了主要目标。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nL4S3SX0YF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B2B36J28.USD","LU0058720904.USD","LU1057294990.SGD","LU2112291526.USD","BK4599","IE0002141913.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BJJMRZ35.SGD","BK4533","SG9999001440.SGD","LU2468319806.SGD","BK4534","IE0009355771.USD","LU2089984988.USD","LU0122379950.USD","BK4139","LU1023059063.AUD","BK4588","LU1571399168.USD","LU2242652126.USD","IE00BFTCPJ56.SGD","LU0868494617.USD","IE00BJT1NW94.SGD","LU0109394709.USD","LU0889565916.HKD","AMGN","BK4585","BK4581","LU1983299246.USD","LU2242646821.SGD","LU1061106388.HKD","LU0289739699.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":0.0685},{"period":"1month","weight":0.0299},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.1417},{"period":"1year","weight":-0.036},{"period":"ytd","weight":0.1443}],"compareEarnings":[{"period":"1week","weight":0.022},{"period":"1month","weight":0.0491},{"period":"3month","weight":0.2376},{"period":"6month","weight":0.0564},{"period":"1year","weight":0.134},{"period":"ytd","weight":0.067}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安进公司于1980年在加利福尼亚成立，并于1987年成为特拉华州的一家公司。该公司发现、开发、制造和交付创新药物，以对抗世界上一些最棘手的疾病。该公司专注于高度未满足的医疗需求领域，并利用其专业知识努力寻求能够显著改善人们生活的解决方案，同时还能减轻疾病带来的社会和经济负担。该公司在40多年前帮助启动了生物技术产业，并已成长为世界领先的独立生物技术公司之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.034093},{"month":2,"riseRate":0.47619,"avgChangeRate":-0.001155},{"month":3,"riseRate":0.52381,"avgChangeRate":0.019224},{"month":4,"riseRate":0.452381,"avgChangeRate":-0.002852},{"month":5,"riseRate":0.52381,"avgChangeRate":0.024179},{"month":6,"riseRate":0.5,"avgChangeRate":0.003875},{"month":7,"riseRate":0.767442,"avgChangeRate":0.052823},{"month":8,"riseRate":0.619048,"avgChangeRate":0.005154},{"month":9,"riseRate":0.52381,"avgChangeRate":0.002807},{"month":10,"riseRate":0.52381,"avgChangeRate":0.020682},{"month":11,"riseRate":0.619048,"avgChangeRate":0.019128},{"month":12,"riseRate":0.642857,"avgChangeRate":0.047779}],"exchange":"NASDAQ","name":"安进","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.2","shortVersion":"4.34.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安进,AMGN,安进股票,安进股票老虎,安进股票老虎国际,安进行情,安进股票行情,安进股价,安进股市,安进股票价格,安进股票交易,安进股票购买,安进股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}